Our Pricing

Mounjaro vs Orlistat UK Comparison

When evaluating mounjaro vs orlistat uk comparison options, understanding the fundamental differences between these two MHRA-licensed weight loss treatments is essential for making an informed choice. Mounjaro (tirzepatide) is a once-weekly injectable dual GIP/GLP-1 receptor agonist, whilst Orlistat is an oral lipase inhibitor taken three times daily with meals. Both require clinical assessment by a UK prescriber, but they work through entirely different mechanisms and produce significantly different results in clinical trials.

How Mounjaro and Orlistat Work Differently

Mounjaro contains tirzepatide, the first dual GIP/GLP-1 receptor agonist licensed by the MHRA for weight management [1]. It activates two natural hormone pathways that regulate appetite, slow gastric emptying, and improve insulin sensitivity. This dual mechanism produces substantial weight loss by reducing hunger signals and increasing feelings of fullness between meals.

Orlistat works through a completely different pathway. As a gastrointestinal lipase inhibitor, it blocks approximately 30% of dietary fat absorption in the intestines [2]. The unabsorbed fat is then eliminated through bowel movements. Unlike Mounjaro, Orlistat does not affect appetite hormones or brain signalling—it purely prevents fat digestion. This means patients must actively reduce dietary fat intake to minimise gastrointestinal side effects.

The mechanistic difference explains why clinical outcomes vary so significantly. Mounjaro addresses the neurological and hormonal drivers of obesity, whilst Orlistat requires strict dietary compliance and only affects one component of calorie absorption. Patients on Mounjaro typically report reduced cravings and natural portion control, whereas Orlistat users must consciously monitor fat intake to avoid treatment-related side effects.

Clinical Efficacy: Mounjaro vs Orlistat Weight Loss Results

In the SURPASS-3 trial, patients receiving the highest Mounjaro dose (15mg weekly) achieved an average body weight reduction of 22.5% over 72 weeks [1]. Even the lowest therapeutic dose (5mg weekly) produced average weight loss exceeding 15% of initial body weight. These results represent some of the most substantial weight reductions observed in obesity pharmacotherapy trials.

By contrast, Orlistat clinical trials demonstrate more modest outcomes. A comprehensive meta-analysis of Orlistat studies found average weight loss of 2.9kg more than placebo over 12 months, translating to approximately 3-5% additional body weight reduction when combined with dietary restriction [2]. Patients typically lose around 5-10% of their starting weight when Orlistat is combined with a reduced-calorie, low-fat diet.

The efficacy gap reflects both mechanism and adherence challenges. Mounjaro's once-weekly injection offers consistent pharmacological action regardless of meal timing, whilst Orlistat requires three doses daily with meals and strict fat restriction. Clinical experience shows that patients often discontinue Orlistat due to gastrointestinal side effects when dietary fat intake is not adequately controlled, whereas Mounjaro's side effect profile typically improves after the initial titration period.

Long-Term Weight Maintenance Outcomes

Long-term data from the SURMOUNT-4 trial demonstrated that patients who discontinued Mounjaro after achieving weight loss regained a significant portion of lost weight, whilst those continuing treatment maintained their reductions [3]. This highlights that Mounjaro, like other GLP-1 treatments, typically requires ongoing use for sustained benefit. Orlistat similarly requires continuous use, though the modest weight loss achieved may be easier to maintain through dietary changes alone once treatment stops.

Side Effects and Tolerability: What UK Patients Experience

Mounjaro's most common side effects are gastrointestinal and include nausea, diarrhoea, vomiting, and constipation, particularly during dose escalation [1]. These effects typically diminish after the first 4-8 weeks as the body adapts. Most UK prescribers start patients on the lowest dose (2.5mg weekly) and gradually increase every four weeks to minimise these symptoms. Serious side effects are rare but include potential thyroid concerns and pancreatitis risk, which is why thorough medical history screening is essential.

Orlistat's side effect profile is distinctly different and directly related to its mechanism. The most frequently reported effects include oily spotting, flatulence with discharge, urgent bowel movements, and fatty or oily stools [2]. These effects worsen when patients consume meals containing more than 15-20g of fat, creating a behavioural deterrent to high-fat eating. Some patients find these effects manageable with strict dietary control, whilst others find them socially limiting and discontinue treatment.

From a clinical perspective, Mounjaro's side effects are generally time-limited and improve with continued use, whereas Orlistat's effects persist throughout treatment whenever dietary fat intake is elevated. Patient preference often depends on whether they find temporary nausea or ongoing bowel-related effects more acceptable. Your UK prescriber will discuss your lifestyle, dietary habits, and tolerability concerns when recommending the most suitable option.

Managing Side Effects in Clinical Practice

For Mounjaro users, eating smaller portions, avoiding high-fat meals, and staying well-hydrated can significantly reduce nausea and gastrointestinal discomfort during the initial weeks. For Orlistat, maintaining a daily fat intake below 60-70g spread across three meals minimises treatment-related bowel effects. Our clinical team at Cured Pharmacy provides detailed guidance on managing side effects when you begin either treatment following prescriber approval.

Mounjaro vs Orlistat: Suitability and Eligibility Criteria

Mounjaro is licensed in the UK for adults with a BMI of 30 kg/m² or above, or 27 kg/m² or above with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidaemia [4]. It is not suitable for patients with a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or severe gastrointestinal disease. Pregnancy and breastfeeding are contraindications, and patients planning pregnancy should discontinue treatment at least two months before conception.

Orlistat has broader eligibility and is available for adults with a BMI of 28 kg/m² or above, making it accessible to patients who do not meet the criteria for injectable treatments [2]. It is also suitable for patients who prefer oral medication or have contraindications to GLP-1 receptor agonists. However, Orlistat is not recommended for patients with chronic malabsorption syndrome, cholestasis, or those taking ciclosporin. It can also reduce absorption of fat-soluble vitamins, so supplementation may be advised.

Your UK prescriber will assess your full medical history, current medications, weight loss goals, and lifestyle factors during your online consultation. Patients with significant weight to lose and no contraindications to injectable treatments often achieve better outcomes with Mounjaro, whilst those seeking a more affordable oral option with modest goals may find Orlistat appropriate. Both treatments require commitment to dietary and lifestyle changes for optimal results.

Cost Comparison: Mounjaro vs Orlistat UK Pricing

At Cured Pharmacy, Mounjaro is available from £135.00 per month, with pricing varying based on your prescribed dose following clinical assessment. This includes your UK prescriber consultation, genuine UK-licensed medication, and discreet home delivery. Mounjaro represents a premium investment in weight management, reflecting its advanced dual-receptor mechanism and superior clinical efficacy demonstrated in trials.

Orlistat offers a more budget-friendly option for UK patients, with generic Orlistat capsules starting from £135.00 per month and branded Xenical from £135.00 at Cured Pharmacy. The lower cost makes it accessible for patients who may not meet funding criteria for injectable treatments or prefer to start with a less expensive option. However, the modest weight loss outcomes mean some patients later transition to more effective treatments if results are insufficient.

When evaluating cost-effectiveness, consider the magnitude of weight loss achieved. Mounjaro's significantly greater efficacy may justify the higher monthly cost for patients with substantial weight to lose or those who have not succeeded with oral treatments. Orlistat's affordability makes it a reasonable first-line option for patients with lower BMI or those seeking gradual, modest weight reduction. Your prescriber will discuss treatment costs transparently during your consultation, and all prices are shown upfront before you complete your clinical assessment.

NHS vs Private Prescription Costs

Both Mounjaro and Orlistat are available on NHS prescription in certain circumstances, typically through specialist weight management services with strict eligibility criteria. However, NHS availability varies significantly by region and often involves lengthy waiting times. Private prescription through UK-registered online pharmacies like Cured Pharmacy offers immediate access following clinical approval, with transparent pricing and convenient home delivery.

Which Treatment Is Right for You? Clinical Guidance

Choosing between Mounjaro and Orlistat depends on your individual circumstances, weight loss goals, medical history, and budget. Mounjaro is typically the preferred choice for patients seeking substantial weight loss (15-20% or more of body weight), those who have not achieved adequate results with oral treatments, or patients with obesity-related comorbidities requiring significant intervention. The once-weekly injection offers convenience and powerful appetite suppression that many patients find transformative.

Orlistat may be more suitable if you have a BMI in the lower obesity range (28-32 kg/m²), prefer oral medication, have contraindications to GLP-1 treatments, or are working with a tighter budget. It is also appropriate for patients who are willing to make significant dietary changes and can tolerate the gastrointestinal side effects associated with fat malabsorption. Some patients successfully use Orlistat as an initial treatment before progressing to injectable options if further weight loss is needed.

At Cured Pharmacy, our UK-registered prescribers assess your complete medical profile during your free online consultation, which takes under three minutes to complete. We offer both treatments with transparent upfront pricing, genuine UK-licensed medication, and discreet delivery. Whether you choose Mounjaro, Orlistat, or another weight loss treatment from our range, you will receive ongoing clinical support and guidance throughout your weight management journey.

Starting Your Weight Loss Treatment at Cured Pharmacy

Begin by completing our confidential online consultation, where you will answer questions about your medical history, current health status, and weight loss goals. A UK prescriber will review your assessment and determine the most appropriate treatment option. If approved, your medication is dispensed by our GPhC-registered pharmacy and delivered discreetly to your door. Our clinical team remains available for ongoing support, dose adjustments, and any questions throughout your treatment.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
2. Rucker, D., Padwal, R., Li, S. K., Curioni, C., & Lau, D. C. (2007). Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ, 335(7631), 1194–1199. https://doi.org/10.1136/bmj.39385.413113.25
3. Aronne, L. J., Sattar, N., Horn, D. B., et al. (2024). Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA, 331(1), 38–48. https://doi.org/10.1001/jama.2023.24945
4. Medicines and Healthcare products Regulatory Agency. (2023). Mounjaro 2.5 mg solution for injection in pre-filled pen - Summary of Product Characteristics. https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary, and weight loss outcomes depend on adherence to treatment and lifestyle modifications.